| Today’s Big NewsJun 4, 2025 |
| By Angus Liu AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu looks poised to reach newly diagnosed patients, with efficacy data that live up to the pair’s previous “highly statistically significant” description. |
|
|
|
By Angus Liu Already boasting a strong foothold in metastatic triple-negative breast cancer, Gilead Sciences’ Trodelvy has produced positive data that could make the antibody-drug conjugate part of a new front-line standard of care. |
By Darren Incorvaia The Trump administration's proposed funding cuts to the National Institutes of Health, including the National Cancer Institute, “would be devastating to the pace and progress of cancer research in America” if they are implemented, the CEO of the American Society of Clinical Oncology said in a May 30 statement. |
By Gabrielle Masson The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. |
By James Waldron AstraZeneca has produced data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival in a phase 3 breast cancer study. |
By Angus Liu The T-cell engager has shown that it can help patients live longer, has a more tolerable safety profile and improves certain cancer-related symptoms compared with chemotherapy in second-line small cell lung cancer. |
By Angus Liu Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the needle in resected skin cancer. |
By Gabrielle Masson Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell carcinoma. But the chase is still in its early days and is likely too soon to call. |
By Gabrielle Masson Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities occurring in patients with advanced B-cell lymphoma. The therapy was also tied to a complete response rate of 78% for patients receiving the highest cell therapy dose. |
By Gabrielle Masson Immatics’ cell therapy has been linked to a 56% objective response rate among 32 heavily pretreated patients with metastatic melanoma. |
By Zoey Becker Itovebi, when added to Pfizer’s Ibrance and AstraZeneca’s Faslodex, cut the risk of death by 33% in a phase 3 trial of certain breast cancer patients. |
By Angus Liu Johnson & Johnson’s Akeega is giving the PARP inhibitor class a first win in castration-sensitive prostate cancer, although the drug’s benefit in a patient subgroup remains unclear. |
By Gabrielle Masson Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have prompted the company and partner Taiho Oncology to pursue an accelerated approval. |
By Angus Liu Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future contenders. |
By James Waldron Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase kinase‐3 beta (GSK-3β) drug showed a three-month survival increase in a phase 2 study. |
By Angus Liu AstraZeneca’s Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. |
By Zoey Becker Pfizer's Braftovi, combined with Eli Lilly's Erbitux and chemo, won an accelerated approval last year through the FDA's Project FrontRunner. Now, the company is working toward a potential full approval. |
By James Waldron Innate Pharma has produced long-term data showing that its anti-KIR3DL2 antibody has a “sustained effect” against two types of lymphoma. |
By James Waldron Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA mulls whether to greenlight the selective menin inhibitor. |
By James Waldron OSE Immunotherapeutics has shared the survival data behind its therapeutic vaccine’s phase 2 pancreatic cancer win, backing up its claims of a “pipeline in a product” potential for the asset. |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how NLP and generative AI, including models like ChatGPT, are transforming precision medicine and life sciences. Sponsored by: IMO Health |
| |
|
